Recent studies on long-acting GLP-1s in type 1 diabetes have shown promising results, including reductions in A1C levels and increased time within the target blood sugar range, without diabetic ketoacidosis or significant hypoglycemic episodes.It is well-established that elevated A1C levels can increase the risk of cardiovascular complications and kidney disease in individuals with T1D
What are the side effects of tirzepatide, and how do they compare to phentermine
=0.0013) and in obese men (from 59 mmol/180 min to 96 mmol/180 min
Dal Bello G, Gisondi P, Idolazzi L, Girolomoni G
The gap between the ad and reality is significant
What Medicares Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries The Centers for Medicare & Medicaid Services (CMS) has released a memo fleshing out the design of a short-term program providing Medicare coverage of GLP-1s for obesity in 2026 ahead of a multi-year demonstration program beginning in 2027